Semeglutide API ea Shenzhen JYMed e amoheloang ke sehlopha sa pele sa NMPA ea malapeng 'me e Ngolisitsoe ho US FDA (DMF No. 036009) e nang le boemo "A".

Ka May 2022, Shenzhen JYMed Technology Co., Ltd. (eo ka mor'a moo e bitsoang JYMed peptide) e ile ea kenya kopo ea ho ngolisoa ha semaglutide API ho US Food and Drug Administration (FDA) (nomoro ea ngoliso ea DMF: 036009), E fetile. tlhahlobo ea botšepehi, 'me boemo ba hajoale ke "A".JYMed peptide e fetohile e 'ngoe ea lihlopha tsa pele tsa baetsi ba semaglutide API Chaena ho fetisa tlhahlobo ea US FDA.

Ka la 16 Pherekhong 2023, webosaete ea semmuso ea Setsi sa Tlhahlobo ea Lithethefatsi sa Tsamaiso ea Lithethefatsi ea Naha e phatlalalitse hore semaglutide API [nomoro ea ngoliso: Y20230000037] e ngolisitsoe mme e phatlalalitsoe ke Hubei JXBio Co., Ltd., motlatsi oa JYMed peptide, e fumane amoheloa.JYMed peptide e fetohile e 'ngoe ea baetsi ba lithethefatsi ba pele ba lihlahisoa tseo kopo ea bona ea ho rekisa sehlahisoa sena e amohetsoeng Chaena.

Mabapi le semaglutide
Semaglutide ke GLP-1 receptor agonist e entsoeng ke Novo Nordisk (Novo Nordisk).Setlhare se ka eketsa metabolism ea tsoekere ka ho susumetsa lisele tsa pancreatic β hore li hlahise insulin, le ho thibela secretion ea glucagon ho tsoa liseleng tsa pancreatic α ho fokotsa ho itima lijo le tsoekere ea mali ka mor'a ho ja.Ho phaella moo, e fokotsa ho ja lijo ka ho fokotsa takatso ea lijo le ho fokotsa tšilo ea lijo ka mpeng, e leng se qetellang se fokotsa mafura a 'mele le ho thusa ho theola boima ba' mele.
1. Boitsebiso ba motheo
Ho latela pono ea sebopeho, ha e bapisoa le liraglutide, phetoho e kholo ka ho fetisisa ea semaglutide ke hore li-AEEA tse peli li kentsoe ketane ea lehlakore la lysine, mme acid ea palmitic e nkeloe sebaka ke octadecanedioic acid.Alanine e ile ea nkeloa sebaka ke Aib, e ileng ea atolosa haholo halofo ea bophelo ba semaglutide.

Setšoantšo Sebopeho sa semaglutide

2. Lipontšo
1) Semaglutide e ka fokotsa kotsi ea liketsahalo tsa pelo ho bakuli ba T2D.
2) Semaglutide e theola tsoekere ea mali ka ho susumetsa secretion ea insulin le ho fokotsa secretion ea glucagon.Ha tsoekere ea mali e phahame, tlhahiso ea insulin ea hlohlelletsoa mme tlhahiso ea glucagon ea thibeloa.
3) Teko ea kliniki ea Novo Nordisk PIONEER e bontšitse hore tsamaiso ea molomo ea semaglutide 1mg, 0.5mg e na le liphello tse molemo tsa hypoglycemic le boima ba 'mele ho feta Trulicity (dulaglutide) 1.5mg, 0.75mg.
3) Oral semaglutide ke karete ea terompeta ea Novo Nordisk.Tsamaiso ea molomo hang ka letsatsi e ka tlosa tšitiso le tlhokofatso ea kelello e bakoang ke ente, 'me e molemo ho feta liraglutide (ente hang ka beke).Litlamorao tsa hypoglycemic le ho theola boima ba 'mele tsa lithethefatsi tse tloaelehileng tse kang empagliflozin (SGLT-2) le sitagliptin (DPP-4) li khahla haholo ho bakuli le lingaka.Ha ho bapisoa le lihlahisoa tsa ente, litlolo tsa molomo li tla ntlafatsa haholo boiketlo ba tšebeliso ea meriana ea semaglutide.

3. Kakaretso
Ke hantle ka lebaka la ts'ebetso ea eona e ntle haholo ea hypoglycemic, tahlehelo ea boima ba 'mele, polokeho le melemo ea pelo eo semaglutide e fetohileng "naleli e ncha" e nang le tebello e kholo ea maraka.